Anixa Biosciences shares rise 10.94% premarket after announcing positive Phase 1 breast cancer vaccine data meeting primary endpoints.

Anixa Biosciences surged 10.94% in premarket trading following the announcement that its investigational breast cancer vaccine met primary endpoints in Phase 1 trials, with the company clarifying details of a poster presentation on its website. The positive clinical data, published on April 17, highlights progress in its oncology pipeline, signaling potential therapeutic advancements and renewed investor confidence in the stock’s long-term prospects.